Sugi Predict

Sugi Predict / Compounds / SCHEMBL2103952

SCHEMBL2103952

SCHEMBL2103952

CN(C)Cc1cc2cc(N)ccc2o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 1/20 0.50
▸ ACHE P22303 3/20 0.44
▸ CA2 P00918 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ DRD2 P14416 1/20 0.38
▸ MAOA P21397 1/20 0.38
▸ F2 P00734 1/20 0.38
▸ F10 P00742 1/20 0.38
▸ RAB9A P51151 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ CASP3 P42574 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ LOXL2 Q9Y4K0 1/20 0.37
▸ APP P05067 2/20 0.36
▸ CHRM2 P08172 1/20 0.35
▸ CHRM4 P08173 1/20 0.35
▸ CHRM5 P08912 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12394347 0.83 PRKCI (0.47) FLT3ACHECA2SMN1; SMN2L3MBTL1
SCHEMBL12708370 0.81 ACHE (0.41) FLT3ACHECA2SMN1; SMN2L3MBTL1
SCHEMBL9677359 0.79 ACHE (0.46) FLT3ACHECA2SMN1; SMN2L3MBTL1
SCHEMBL10419623 0.78 MAOA (0.57) FLT3ACHECA2SMN1; SMN2NPC1
SCHEMBL8179634 0.77 TLR8 (0.47) FLT3ACHECA2NPC1DRD2
SCHEMBL4689215 0.77 FLT3 (0.55) FLT3ACHECA2SMN1; SMN2NPC1
SCHEMBL28282594 0.77 FLT3 (0.50) FLT3ACHECA2SMN1; SMN2NPC1
SCHEMBL9716345 0.76 ACHE (0.38) FLT3ACHECA2SMN1; SMN2L3MBTL1
SCHEMBL13765057 0.76 FLT3 (0.46) FLT3ACHECA2NPC1DRD2
SCHEMBL5438487 0.75 HDAC6 (0.49) L3MBTL1F2F10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110872296-B dihydro-isoindole-1H-pyrazolo [3,4-d ] pyrimidinone compound, and preparation method and application thereof 上海弘翊生物科技有限公司 2023-05-23 — — CN disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
CN-110872296-A isoindoline-1H-pyrazolo [3,4-d ] pyrimidone compound, and preparation method and application thereof 上海弘翊生物科技有限公司 2020-03-10 — — CN disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-9499535-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2016-11-22 — — US disclosed
EP-2699572-B1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2016-08-10 — — EP disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 — — EP disclosed
EP-2316459-B1 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases RIGEL PHARMACEUTICALS INC (US) 2013-11-06 — — EP disclosed
US-8557806-B2 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS, INC. (US) 2013-10-15 — — US disclosed
US-20120329785-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
WO-2012143144-A1 PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 — — WO disclosed
WO-2012143143-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 — — WO disclosed
US-8158621-B2 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS, INC. (US) 2012-04-17 — — US disclosed
US-7825116-B2 -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis RIGEL PHARMACEUTICALS, INC. (US) 2010-11-02 — — US disclosed
US-7812029-B1 such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis RIGEL PHARMACEUTICALS, INC. (US) 2010-10-12 — — US disclosed
US-7517886-B2 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS, INC. (US) 2009-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK FLT3 504/4885ACHE 713/4885CA2 3513/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK FLT3 504/4885ACHE 713/4885CA2 3513/4885
US-20120329785-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK3 FLT3 491/4885ACHE 2231/4885CA2 4069/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK FLT3 407/4885ACHE 686/4885CA2 3360/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK FLT3 407/4885ACHE 686/4885CA2 3360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.